Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Ltd (NASDAQ: CNTB) delivers innovative immune modulation therapies targeting autoimmune diseases and chronic inflammation. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Key resources include: Phase trial results analysis, FDA submission alerts, licensing agreements, and scientific conference presentations. Track progress across the company’s pipeline including CBP-201 (atopic dermatitis) and CBP-307 (ulcerative colitis) candidates.
All content undergoes strict verification to ensure accuracy and relevance. Bookmark this page for consolidated access to earnings reports, management commentary, and peer-reviewed research updates. Check regularly for developments in T-cell modulation therapies and autoimmune treatment advancements.
Connect Biopharma (Nasdaq: CNTB) announced that it is on track to submit a New Drug Application (NDA) for its lead drug candidate, CBP-201, for the treatment of moderate-to-severe atopic dermatitis in China by the end of Q1 2024. The submission could lead to potential approval by 2025. Encouraging results from pivotal trials in China and global data presented at the AAD Annual Meeting support the efficacy of CBP-201. Connect Biopharma has also completed enrollment for a Phase 2 global trial in asthma and reported positive topline data from the ongoing China pivotal trial for CBP-201. However, the company reported a net loss of RMB 797.1 million in 2022, a decrease from RMB 1,306.8 million in 2021, while its cash reserves declined to RMB 1,127.3 million. R&D expenses increased to RMB 652.2 million due to advancing clinical trials.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) presented data from Stage 1 of a pivotal trial for CBP-201 at the American Academy of Dermatology Annual Meeting. The trial, involving 255 adults with moderate-to-severe atopic dermatitis, met all primary and secondary endpoints, showing rapid symptom relief—some within a week—and no efficacy plateau by Week 16. Notably, 30.3% of treated patients achieved clear or almost clear skin. The drug demonstrated a favorable safety profile with mostly mild-to-moderate adverse effects. CEO Zheng Wei highlighted CBP-201's potential for flexible dosing and high unmet medical need in dermatology.
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced promising findings from a Phase 2b global trial for its drug, CBP-201, aimed at treating moderate-to-severe atopic dermatitis (AD). The results, presented at the American Academy of Dermatology Annual Meeting, demonstrated significant improvements in AD symptoms across multiple body regions as early as Week 2, with sustained results observed up to Week 16. Notably, the study showed a substantial decrease in EASI scores, with improvements in erythema and other signs of AD. The trial supports CBP-201's potential as an effective treatment option with flexible dosing regimens.
FAQ
What is the current stock price of Connect Biopharma Holdings (CNTB)?
What is the market cap of Connect Biopharma Holdings (CNTB)?
